DE69207847D1 - Verwendung von Rapamycin zur Herstellung eines Arzneimittels zur Behandlung von Augenentzündungen - Google Patents

Verwendung von Rapamycin zur Herstellung eines Arzneimittels zur Behandlung von Augenentzündungen

Info

Publication number
DE69207847D1
DE69207847D1 DE69207847T DE69207847T DE69207847D1 DE 69207847 D1 DE69207847 D1 DE 69207847D1 DE 69207847 T DE69207847 T DE 69207847T DE 69207847 T DE69207847 T DE 69207847T DE 69207847 D1 DE69207847 D1 DE 69207847D1
Authority
DE
Germany
Prior art keywords
rapamycin
treatment
medicament
manufacture
eye inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69207847T
Other languages
English (en)
Other versions
DE69207847T2 (de
Inventor
Prasad Shrikrishna Kulkarni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Louisville Research Foundation ULRF
Original Assignee
University of Louisville Research Foundation ULRF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Louisville Research Foundation ULRF filed Critical University of Louisville Research Foundation ULRF
Publication of DE69207847D1 publication Critical patent/DE69207847D1/de
Application granted granted Critical
Publication of DE69207847T2 publication Critical patent/DE69207847T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Eye Examination Apparatus (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69207847T 1991-07-25 1992-07-24 Verwendung von Rapamycin zur Herstellung eines Arzneimittels zur Behandlung von Augenentzündungen Expired - Lifetime DE69207847T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73560491A 1991-07-25 1991-07-25

Publications (2)

Publication Number Publication Date
DE69207847D1 true DE69207847D1 (de) 1996-03-07
DE69207847T2 DE69207847T2 (de) 1996-05-30

Family

ID=24956475

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69207847T Expired - Lifetime DE69207847T2 (de) 1991-07-25 1992-07-24 Verwendung von Rapamycin zur Herstellung eines Arzneimittels zur Behandlung von Augenentzündungen

Country Status (20)

Country Link
US (1) US5387589A (de)
EP (1) EP0532862B1 (de)
JP (1) JP2568962B2 (de)
KR (1) KR100216768B1 (de)
AT (1) ATE133336T1 (de)
AU (1) AU653415B2 (de)
CA (1) CA2074641C (de)
CZ (1) CZ285660B6 (de)
DE (1) DE69207847T2 (de)
DK (1) DK0532862T3 (de)
ES (1) ES2083030T3 (de)
HK (1) HK1005705A1 (de)
HU (1) HU211218B (de)
IE (1) IE922430A1 (de)
IL (1) IL102414A (de)
MX (1) MX9204381A (de)
NZ (1) NZ243679A (de)
RU (1) RU2048812C1 (de)
SK (1) SK280511B6 (de)
ZA (1) ZA924953B (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69231644T2 (de) * 1991-04-26 2001-05-23 Fujisawa Pharmaceutical Co Verwendung von makrolid-verbindungen gegen augenerkrankungen
AT408520B (de) * 1993-05-27 2001-12-27 Novartis Erfind Verwalt Gmbh Galenische formulierungen
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
TW427904B (en) * 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
GB9601120D0 (en) * 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
US5912224A (en) * 1996-02-22 1999-06-15 The General Hospital Corporation Methods and compositions for enhancing cellular response to TGF-β ligands
JPH09278653A (ja) * 1996-04-05 1997-10-28 Santen Pharmaceut Co Ltd 網膜疾患治療剤
US5922730A (en) * 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
KR19990048077A (ko) * 1997-12-08 1999-07-05 전원중 인조대리석 성형품의 제조방법
US6384073B1 (en) * 1998-02-23 2002-05-07 Fujisawa Pharmaceutical Co., Ltd. Use of macrolide compounds for treating glaucoma
BR9906772A (pt) * 1998-07-14 2000-09-26 Alcon Lab Inc Uso de ácido 11-(3-dimetilamino-propilideno)-6,11diidrodibenz[b,e]o xepin-2-acético para a fabricação de um medicamento para tratamento de desordens inflamatórias oftálmicas não-alérgicas e para prevenção de neovascularização ocular
US7410995B1 (en) 1998-08-14 2008-08-12 Gpi Nil Holdings Inc. N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders
US6376517B1 (en) * 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US6333340B1 (en) 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6335348B1 (en) 1998-08-14 2002-01-01 Gpi Nil Holdings, Inc. Nitrogen-containing linear and azepinyl/ compositions and uses for vision and memory disorders
US6506788B1 (en) 1998-08-14 2003-01-14 Gpi Nil Holdings, Inc. N-linked urea or carbamate of heterocyclic thioesters for vision and memory disorders
US7265150B1 (en) 1998-08-14 2007-09-04 Gpi Nil Holdings Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders
US7338976B1 (en) 1998-08-14 2008-03-04 Gpi Nil Holdings, Inc. Heterocyclic esters or amides for vision and memory disorders
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US6384056B1 (en) 1998-08-14 2002-05-07 Gpi Nil Holdings, Inc. Heterocyclic thioesters or ketones for vision and memory disorders
US6399648B1 (en) 1998-08-14 2002-06-04 Gpi Nil Holdings, Inc. N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders
US6337340B1 (en) 1998-08-14 2002-01-08 Gpi Nil Holdings, Inc. Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
NZ513111A (en) * 1998-12-24 2003-10-31 R Tech Ueno Ltd Agent for treating visual cell function disorder
US6864232B1 (en) 1998-12-24 2005-03-08 Sucampo Ag Agent for treating visual cell function disorder
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
EP1173177B2 (de) * 1999-04-30 2014-03-05 Sucampo AG Verwendung von makroliden zur behandlung von trockenen augen
US6331547B1 (en) 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
JP2004509898A (ja) 2000-09-19 2004-04-02 ワイス 水溶性ラパマイシンエステル
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US6534693B2 (en) 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
US20040241211A9 (en) * 2000-11-06 2004-12-02 Fischell Robert E. Devices and methods for reducing scar tissue formation
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
EP1419154B1 (de) 2001-08-22 2005-10-05 Wyeth Rapanycin29-enole
EP1419153A1 (de) 2001-08-22 2004-05-19 Wyeth Rapamycindialdehyde
PL368642A1 (en) * 2001-11-19 2005-04-04 Novartis Ag Use of an ascomycin for the treatment of blepharitis
US20030220297A1 (en) 2002-02-01 2003-11-27 Berstein David L. Phosphorus-containing compounds and uses thereof
JP4265888B2 (ja) * 2002-06-12 2009-05-20 株式会社リコー 画像形成装置
BR0313024A (pt) 2002-07-30 2005-07-12 Wyeth Corp Formulações parenterais contendo um hidroxiéster de rapamicina
CN100415233C (zh) * 2002-09-17 2008-09-03 惠氏公司 口服制剂
PT1539157E (pt) * 2002-09-18 2013-10-04 Univ Pennsylvania Rapamicina para utilização na inibição ou prevenção de neovascularização coroidal
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
AR042938A1 (es) * 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
US20040258662A1 (en) * 2003-04-22 2004-12-23 Wyeth Antineoplastic agents
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
CN1882338A (zh) * 2003-09-18 2006-12-20 马库赛特公司 经巩膜递送
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
CA2582374A1 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
ES2564194T3 (es) 2005-02-09 2016-03-18 Santen Pharmaceutical Co., Ltd. Formulaciones líquidas para el tratamiento de enfermedades o dolencias
BRPI0609432A2 (pt) * 2005-03-21 2010-04-06 Macusight Inc sistemas de distribuição de fármacos para tratamento de doenças ou condições
WO2007027091A2 (en) 2005-05-13 2007-03-08 Akkolens International B.V. Intra-ocular artificial lens for iris-driven accommodation
US20070014760A1 (en) * 2005-07-18 2007-01-18 Peyman Gholam A Enhanced recovery following ocular surgery
PL1904056T3 (pl) 2005-07-18 2009-09-30 Minu Llc Zastosowanie makrolidu do przywracania czucia rogówkowego
US20070071754A1 (en) * 2005-09-26 2007-03-29 Peyman Gholam A Method to ameliorate inflammation
AU2006315512B2 (en) 2005-11-14 2012-11-01 Ariad Pharmaceuticals, Inc. Administration of an mTOR inhibitor to treat patients with cancer
BRPI0707612B8 (pt) * 2006-02-09 2021-05-25 Macusight Inc vaso lacrado e formulações líquidas contidas no mesmo
US8222271B2 (en) 2006-03-23 2012-07-17 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
WO2008022256A2 (en) * 2006-08-16 2008-02-21 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
EP2431036B1 (de) 2006-09-13 2017-04-12 Elixir Medical Corporation Makrocyclische Lactonverbindungen und Verfahren zu deren Verwendung
JP5668476B2 (ja) * 2007-10-08 2015-02-12 オーリニア・ファーマシューティカルズ・インコーポレイテッドＡｕｒｉｎｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． カルシニューリン阻害剤またはｍＴＯＲ阻害剤を含む眼科用組成物
WO2009070530A1 (en) * 2007-11-27 2009-06-04 Alcon Research, Ltd. Topical ophthalmic or otic solution formulations containing moxifloxacin hydrochloride and dexamethasone phosphate
CN102231969A (zh) * 2008-10-03 2011-11-02 万能医药公司 大环内酯化合物及其使用方法
CN104997774A (zh) * 2009-04-10 2015-10-28 齐海燕 新的抗衰老试剂及其鉴别方法
WO2010144194A1 (en) 2009-06-09 2010-12-16 Lux Biosciences, Inc. Topical drug delivery systems for ophthalmic use
US8912215B2 (en) 2011-12-13 2014-12-16 Everon Biosciences, Inc. Rapamycin composition
US20140255355A1 (en) * 2013-03-07 2014-09-11 Stemnion, Inc. Methods for treating blepharitis
CN109152769A (zh) 2016-05-25 2019-01-04 参天制药株式会社 西罗莫司用于治疗伴有持续性水肿的渗出性年龄相关性黄斑变性的用途
MX2018016424A (es) 2016-06-30 2019-08-12 Durect Corp Formulaciones de deposito.
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
EP3576736A4 (de) 2017-02-10 2020-08-26 Torcept Therapeutics Inc. Rapamycinanalogon
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
CA3067332A1 (en) 2017-06-16 2018-12-20 The Doshisha Mtor-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
WO2021132565A1 (ja) 2019-12-26 2021-07-01 参天製薬株式会社 シロリムスまたはその塩を含有する水性懸濁組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) * 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4316885A (en) * 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
AU635286B2 (en) * 1989-07-05 1993-03-18 Astellas Pharma Inc. Aqueous liquid composition for external use

Also Published As

Publication number Publication date
CA2074641C (en) 1999-05-04
HU211218B (en) 1995-11-28
CZ285660B6 (cs) 1999-10-13
HUT63763A (en) 1993-10-28
JP2568962B2 (ja) 1997-01-08
ATE133336T1 (de) 1996-02-15
AU2035092A (en) 1993-01-28
SK230792A3 (en) 1996-05-08
NZ243679A (en) 1997-06-24
JPH05194212A (ja) 1993-08-03
DK0532862T3 (da) 1996-02-19
IL102414A (en) 1996-08-04
EP0532862A1 (de) 1993-03-24
EP0532862B1 (de) 1996-01-24
CA2074641A1 (en) 1993-01-26
IE922430A1 (en) 1993-01-27
KR100216768B1 (ko) 1999-09-01
CZ230792A3 (en) 1993-02-17
HU9202448D0 (en) 1992-10-28
DE69207847T2 (de) 1996-05-30
HK1005705A1 (en) 1999-01-22
IL102414A0 (en) 1993-01-14
AU653415B2 (en) 1994-09-29
ZA924953B (en) 1993-04-28
KR930001913A (ko) 1993-02-22
US5387589A (en) 1995-02-07
ES2083030T3 (es) 1996-04-01
RU2048812C1 (ru) 1995-11-27
MX9204381A (es) 1993-02-01
SK280511B6 (sk) 2000-03-13

Similar Documents

Publication Publication Date Title
DE69207847D1 (de) Verwendung von Rapamycin zur Herstellung eines Arzneimittels zur Behandlung von Augenentzündungen
ATE191143T1 (de) Verwendung von nichtsteroidalen cyclooxygenasehemmern zur herstellung eines medikaments zur behandlung vom erhoehten augeninnendruck
DE69427337T2 (de) Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz
ATE286880T2 (de) Verwendung von fluprostenolisopropylester zur herstellung eines arzneimittels zur behandlung von glaukom und okularer hypertension
DE69719931D1 (de) Verwendung von Acetylcystein zur Herstellung eines Arzneimittels zur Behandlung von chronischen Geschwüren
DE69202019D1 (de) Verwendung von essentiellen Fettsäuren zur Herstellung eines Arzneimittels zur Behandlung von AIDS.
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE69229944T2 (de) Verwendung von N-Acylaminoalkoholen zur Herstellung eines Arzneimittels zur Behandlung von Mastzellerkrankungen
DE69400631D1 (de) Verwendung von rifamycinderivaten zur herstellung eines arzneimittels zur behandlung der toxoplasmose
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
DE59600683D1 (de) Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten
DE69227583D1 (de) Arylmorpholine, herstellung und verwendung
DE69100171D1 (de) Synergistische kombination zur ophthalmischen verwendung.
DE59504374D1 (de) Verwendung von Deoxyspergualin zur Herstellung eines Arzneimittels zur Behandlung von entzündlich-hyperreaktiven Erkrankungen
ATE178336T1 (de) Verwendung einer therapeutischen zusammensetzung zur behandlung von bronchitis
KR920009403A (ko) 수면장해 치료용 이미다조벤조디아제핀
DE69509657T2 (de) Verwendung von benzothiophenen zur herstellung eines medikaments zur verminderung der narbenbildung bei der wundheilung
UA10221A (uk) Спосіб лікування рецидивного бронхіту у дітей
RU94008009A (ru) Способ лечения ожогов глаз
DE69215191T2 (de) Verwendung von thiol-5-(2-diethyl-aminoethyl)-ester-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung der neuromuskuläre Inkontinenz

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R071 Expiry of right

Ref document number: 532862

Country of ref document: EP